OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Randomized Controlled Trial of Early Outpatient COVID-19 Treatment with High-Titer Convalescent Plasma
David J. Sullivan, Kelly A. Gebo, Shmuel Shoham, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 36
David J. Sullivan, Kelly A. Gebo, Shmuel Shoham, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 36
Showing 1-25 of 36 citing articles:
Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With COVID-19 (September 2022)
Adarsh Bhimraj, Rebecca L. Morgan, Amy Hirsch Shumaker, et al.
Clinical Infectious Diseases (2022) Vol. 78, Iss. 7, pp. e250-e349
Open Access | Times Cited: 120
Adarsh Bhimraj, Rebecca L. Morgan, Amy Hirsch Shumaker, et al.
Clinical Infectious Diseases (2022) Vol. 78, Iss. 7, pp. e250-e349
Open Access | Times Cited: 120
COVID-19 Convalescent Plasma and Clinical Trials: Understanding Conflicting Outcomes
Daniele Focosi, Massimo Franchini, Liise-anne Pirofski, et al.
Clinical Microbiology Reviews (2022) Vol. 35, Iss. 3
Open Access | Times Cited: 89
Daniele Focosi, Massimo Franchini, Liise-anne Pirofski, et al.
Clinical Microbiology Reviews (2022) Vol. 35, Iss. 3
Open Access | Times Cited: 89
Sulforaphane exhibits antiviral activity against pandemic SARS-CoV-2 and seasonal HCoV-OC43 coronaviruses in vitro and in mice
Alvaro A. Ordoñez, C. Korin Bullen, A.F. Villabona-Rueda, et al.
Communications Biology (2022) Vol. 5, Iss. 1
Open Access | Times Cited: 69
Alvaro A. Ordoñez, C. Korin Bullen, A.F. Villabona-Rueda, et al.
Communications Biology (2022) Vol. 5, Iss. 1
Open Access | Times Cited: 69
Convalescent plasma with a high level of virus-specific antibody effectively neutralizes SARS-CoV-2 variants of concern
Maggie Li, E. Beck, Oliver Laeyendecker, et al.
Blood Advances (2022) Vol. 6, Iss. 12, pp. 3678-3683
Open Access | Times Cited: 54
Maggie Li, E. Beck, Oliver Laeyendecker, et al.
Blood Advances (2022) Vol. 6, Iss. 12, pp. 3678-3683
Open Access | Times Cited: 54
Convalescent plasma therapy in COVID-19: Unravelling the data using the principles of antibody therapy
Arturo Casadevall, Michael J. Joyner, Liise-anne Pirofski, et al.
Expert Review of Respiratory Medicine (2023) Vol. 17, Iss. 5, pp. 381-395
Closed Access | Times Cited: 25
Arturo Casadevall, Michael J. Joyner, Liise-anne Pirofski, et al.
Expert Review of Respiratory Medicine (2023) Vol. 17, Iss. 5, pp. 381-395
Closed Access | Times Cited: 25
Antibodies from convalescent plasma promote SARS-CoV-2 clearance in individuals with and without endogenous antibody response
Maddalena Marconato, Irène A. Abela, Anthony Hauser, et al.
Journal of Clinical Investigation (2022) Vol. 132, Iss. 12
Open Access | Times Cited: 32
Maddalena Marconato, Irène A. Abela, Anthony Hauser, et al.
Journal of Clinical Investigation (2022) Vol. 132, Iss. 12
Open Access | Times Cited: 32
Immunity to SARS-CoV-2: What Do We Know and Should We Be Testing for It?
Anisha Misra, Elitza S. Theel
Journal of Clinical Microbiology (2022) Vol. 60, Iss. 6
Open Access | Times Cited: 30
Anisha Misra, Elitza S. Theel
Journal of Clinical Microbiology (2022) Vol. 60, Iss. 6
Open Access | Times Cited: 30
Determinants of passive antibody efficacy in SARS-CoV-2 infection: a systematic review and meta-analysis
Eva Stadler, Khai Li Chai, Timothy E. Schlub, et al.
The Lancet Microbe (2023) Vol. 4, Iss. 11, pp. e883-e892
Open Access | Times Cited: 20
Eva Stadler, Khai Li Chai, Timothy E. Schlub, et al.
The Lancet Microbe (2023) Vol. 4, Iss. 11, pp. e883-e892
Open Access | Times Cited: 20
Differential efficacy and safety of anti-SARS-CoV-2 antibody therapies for the management of COVID-19: a systematic review and network meta-analysis
Jiawen Deng, Kiyan Heybati, Harikrishnaa Ba Ramaraju, et al.
Infection (2022) Vol. 51, Iss. 1, pp. 21-35
Open Access | Times Cited: 26
Jiawen Deng, Kiyan Heybati, Harikrishnaa Ba Ramaraju, et al.
Infection (2022) Vol. 51, Iss. 1, pp. 21-35
Open Access | Times Cited: 26
Pathophysiology, Diagnosis, Treatment, and Genetics of Carpal Tunnel Syndrome: A Review
Mahshid Malakootian, Mahdieh Soveizi, Akram Gholipour, et al.
Cellular and Molecular Neurobiology (2022) Vol. 43, Iss. 5, pp. 1817-1831
Closed Access | Times Cited: 22
Mahshid Malakootian, Mahdieh Soveizi, Akram Gholipour, et al.
Cellular and Molecular Neurobiology (2022) Vol. 43, Iss. 5, pp. 1817-1831
Closed Access | Times Cited: 22
Prospective individual patient data meta-analysis of two randomized trials on convalescent plasma for COVID-19 outpatients
Pere Millat-Martínez, Arvind Gharbharan, Andrea Alemany, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 21
Pere Millat-Martínez, Arvind Gharbharan, Andrea Alemany, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 21
Nucleocapsid-specific antibody function is associated with therapeutic benefits from COVID-19 convalescent plasma therapy
Jonathan D. Herman, Chuangqi Wang, John S. Burke, et al.
Cell Reports Medicine (2022) Vol. 3, Iss. 11, pp. 100811-100811
Open Access | Times Cited: 19
Jonathan D. Herman, Chuangqi Wang, John S. Burke, et al.
Cell Reports Medicine (2022) Vol. 3, Iss. 11, pp. 100811-100811
Open Access | Times Cited: 19
How do I implement an outpatient program for the administration of convalescent plasma for COVID ‐19?
Evan M. Bloch, Aaron A.R. Tobian, Shmuel Shoham, et al.
Transfusion (2022) Vol. 62, Iss. 5, pp. 933-941
Open Access | Times Cited: 18
Evan M. Bloch, Aaron A.R. Tobian, Shmuel Shoham, et al.
Transfusion (2022) Vol. 62, Iss. 5, pp. 933-941
Open Access | Times Cited: 18
Evaluation of Antibody-Dependent Fc-Mediated Viral Entry, as Compared With Neutralization, in SARS-CoV-2 Infection
Lindsay Wieczorek, Michelle Zemil, Mélanie Merbah, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 12
Lindsay Wieczorek, Michelle Zemil, Mélanie Merbah, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 12
Convalescent plasma in outpatients with COVID-19
Daniele Focosi, Arturo Casadevall
The Lancet Respiratory Medicine (2022) Vol. 10, Iss. 3, pp. 226-228
Open Access | Times Cited: 11
Daniele Focosi, Arturo Casadevall
The Lancet Respiratory Medicine (2022) Vol. 10, Iss. 3, pp. 226-228
Open Access | Times Cited: 11
Comparison of Preprint Postings of Randomized Clinical Trials on COVID-19 and Corresponding Published Journal Articles
Anthony D. Bai, Yunbo Jiang, David Nguyen, et al.
JAMA Network Open (2023) Vol. 6, Iss. 1, pp. e2253301-e2253301
Open Access | Times Cited: 5
Anthony D. Bai, Yunbo Jiang, David Nguyen, et al.
JAMA Network Open (2023) Vol. 6, Iss. 1, pp. e2253301-e2253301
Open Access | Times Cited: 5
A role for Nucleocapsid-specific antibody function in Covid-19 Convalescent plasma therapy
Jonathan D. Herman, Chuangqi Wang, John S. Burke, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 8
Jonathan D. Herman, Chuangqi Wang, John S. Burke, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 8
Antibody attributes that predict the neutralization and effector function of polyclonal responses to SARS-CoV-2
Harini Natarajan, Shiwei Xu, Andrew R. Crowley, et al.
BMC Immunology (2022) Vol. 23, Iss. 1
Open Access | Times Cited: 8
Harini Natarajan, Shiwei Xu, Andrew R. Crowley, et al.
BMC Immunology (2022) Vol. 23, Iss. 1
Open Access | Times Cited: 8
The efficiency of convalescent plasma in COVID-19 patients: A systematic review and meta-analysis of randomized controlled clinical trials
Zhenbei Qian, Zhijin Zhang, Haomiao Ma, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 8
Zhenbei Qian, Zhijin Zhang, Haomiao Ma, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 8
WHO covid-19 drugs guideline: reconsider using convalescent plasma
Nigel Paneth, Arturo Casadevall, Liise-anne Pirofski, et al.
BMJ (2022), pp. o295-o295
Closed Access | Times Cited: 7
Nigel Paneth, Arturo Casadevall, Liise-anne Pirofski, et al.
BMJ (2022), pp. o295-o295
Closed Access | Times Cited: 7
The Efficiency of Convalescent Plasma Therapy in the Management of Critically Ill Patients Infected With COVID-19: A Matched Cohort Study
Chun Pan, Hui Chen, Jianfeng Xie, et al.
Frontiers in Medicine (2022) Vol. 9
Open Access | Times Cited: 7
Chun Pan, Hui Chen, Jianfeng Xie, et al.
Frontiers in Medicine (2022) Vol. 9
Open Access | Times Cited: 7
Antispike monoclonal antibodies for prevention and treatment of coronavirus disease-2019 in solid organ transplant recipients
Zachary A. Yetmar, Eric Bhaimia, Raymund R. Razonable
Current Opinion in Organ Transplantation (2022) Vol. 27, Iss. 4, pp. 269-276
Open Access | Times Cited: 6
Zachary A. Yetmar, Eric Bhaimia, Raymund R. Razonable
Current Opinion in Organ Transplantation (2022) Vol. 27, Iss. 4, pp. 269-276
Open Access | Times Cited: 6
COVID-19 convalescent plasma and randomized clinical trials: explaining conflicting outcomes and finding signals of efficacy
Daniele Focosi, Massimo Franchini, Liise-anne Pirofski, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 7
Daniele Focosi, Massimo Franchini, Liise-anne Pirofski, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 7
Immunotherapy and CRISPR Cas Systems: Potential Cure of COVID-19?
Xuesong He, Xiao Xue Zeng
Drug Design Development and Therapy (2022) Vol. Volume 16, pp. 951-972
Open Access | Times Cited: 5
Xuesong He, Xiao Xue Zeng
Drug Design Development and Therapy (2022) Vol. Volume 16, pp. 951-972
Open Access | Times Cited: 5
Convalescent Plasma Therapy against COVID-19: An Update on the Changing Facets of the ongoing Pandemic
Saquib S. Abullais, Suraj Arora, Shadma Wahab, et al.
Current Pharmaceutical Biotechnology (2023) Vol. 24, Iss. 12, pp. 1515-1523
Closed Access | Times Cited: 2
Saquib S. Abullais, Suraj Arora, Shadma Wahab, et al.
Current Pharmaceutical Biotechnology (2023) Vol. 24, Iss. 12, pp. 1515-1523
Closed Access | Times Cited: 2
